Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Acinic Cell Carcinoma of the Parotid Gland in Children and Adolescents

Ash, Shifra MD*,†; Yaniv, Isaac MD*,†; Feinmesser, Raphael MD†,‡; Konen, Osnat MD†,§; Feinmesser, Meora MD†,∥

Journal of Pediatric Hematology/Oncology: March 2018 - Volume 40 - Issue 2 - p 99–103
doi: 10.1097/MPH.0000000000000994
Original Articles
Buy

Acinic cell carcinoma of the parotid gland is a rare low-grade malignant neoplasm. Data on children are sparse. For the present study, the database of a tertiary pediatric medical center was reviewed for all patients with parotid gland acinic cell carcinoma diagnosed and treated between 2004 and 2013. Clinical, histologic, treatment, and outcome parameters were collected from the medical files. Four patients were identified, 3 female and 1 male, aged 13.5 to 18 years (median 15.7) at diagnosis. One patient had a family history of parotid tumor and 1 of hypothyroidism/hyperthyroidism. Two patients had L-thyroxin-treated Hashimoto thyroiditis, and 1 had a thyroid nodule. All presented with a localized parotid mass and negative lymph nodes. Treatment consisted of partial parotidectomy, with no damage to the facial nerve. Histology confirmed the diagnosis of acinic cell carcinoma with low proliferation rate (Ki67 immunostaining 1% to 8%). No evidence of disease was found on any patient with a median follow-up at 83 months (range, 32 to 93 mo) from presentation. In our experience, the prognosis of pediatric parotid gland acinic cell carcinoma is good, and surgery alone is sufficient for treatment of early stage tumors. This is the first report of findings of a family history of thyroid disease and/or thyroid abnormalities in patients with parotid gland acinic cell carcinoma.

*Departments of Pediatric Hematology-Oncology

§Radiology, Schneider Children’s Medical Center of Israel

Departments of Otolaryngology

Pathology, Rabin Medical Center, Beilinson Hospital, Petah Tikva

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

The authors declare no conflict of interest.

Reprints: Shifra Ash, MD, Department of Pediatric Hematology-Oncology, Schneider Children’s Medical Center of Israel, 14 Kaplan Street, Petah Tikva 4920235, Israel (e-mail: shifraa@clalit.org.il).

Received May 9, 2016

Accepted May 31, 2017

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.